Irinotecan Injection and Pacritinib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Irinotecan Injection
Pacritinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions
Interaction Deep Dive
Coadministration of pacritinib (BCRP inhibitor) and BCRP substrates may increase BCRP substrates exposure, which may increase the risk of adverse reactions from the BCRP substrates. When used concomitantly with pacritinib, monitor for BCRP substrate related adverse reactions more frequently and consider dose reduction of the BCRP substrate. In a drug interaction study, coadministration of pacritinib dose of 200 mg twice daily and rosuvastatin 5 mg resulted in an increase in rosuvastatin AUC by 1.80-fold and Cmax by 2-fold1.
Why it happens (mechanism)
Inhibition of BCRP-mediated efflux transport by pacritinib
Literature reports
1 report — tap to read
a) In a drug interaction study, coadministration of pacritinib dose of 200 mg twice daily and rosuvastatin 5 mg resulted in an increase in rosuvastatin AUC by 1.80-fold and Cmax by 2-fold 1.
Common questions
Can I take Irinotecan Injection and Pacritinib together?
Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Irinotecan Injection and Pacritinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Irinotecan Injection or Pacritinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VONJO(R) oral capsules, pacritinib oral capsules. CTI BioPharma Corp (per FDA), Seattle, WA, 2024. DailyMed
Keep reading about Irinotecan Injection
Keep reading about Pacritinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist